MetaCap

CDT Equity (CDT) vs SciSparc (SPRC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SciSparc is the larger company by market cap ($481,603 vs $437,033), about 1.1 times the size. On valuation, CDT Equity trades at a lower trailing P/E (0.0x vs 0.0x for SciSparc).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CDT-72.49%SPRC-95.79%
+64%-20%-103%
Oct 7, 20261 yearNov 20, 2026
CDT-67.97%SPRC-95.63%
+91%-7%-105%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CDT versus SPRC key metrics
MetricCDTSPRC
Share price$0.23$0.1955
Market cap$437.03K$481.60K
1-day change-13.89%-34.83%
P/E ratio (TTM)0.000.00
EPS (TTM)$1,816,250.00$248.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.31M
Revenue growth (YoY)—-54.64%
Net income (latest FY)$-39.22M$-6.28M
Gross margin—38.74%
Operating margin—-560.18%
Net margin—-481.16%
52-week high$291,250.00$29.88
52-week low$0.223$0.167
Distance from 52-week high-100.00%-99.35%
Average volume956.66K2.93M
Shares outstanding1.90M2.46M
Employees43
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SciSparc trades at a higher earnings multiple (0.0x vs 0.0x trailing P/E).

About CDT Equity

CDT stock →

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About SciSparc

SPRC stock →

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

CDT vs SPRC FAQ

Which is bigger, CDT Equity or SciSparc?

SciSparc (SPRC) is larger, with a market capitalization of $481.60K compared with $437.03K for CDT Equity (CDT).

Which has the lower P/E ratio, CDT or SPRC?

CDT has the lower trailing P/E at 0.0, versus 0.0 for SPRC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are CDT Equity and SciSparc in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons